Destiny Pharma plc

12:00 PM - 12:15 PM (PDT), Wednesday, June 15, 2022
Destiny Pharma PLC is a public UK biotech company listed on AIM with clinically proven novel drug assets. It has two late-stage clinical assets which it is preparing for Phase 3 studies -

NTCD-M3 for prevention of recurrence of C. difficile infection; and
XF-73 for prevention of post-surgical S. aureus infections.

It is seeking commercialisation partners for these assets in the major territories outside China.

Beyond this, it has a pipeline related to its proprietary and patent protected XF platform; and separately a preclinical stage collaboration focused on COVID-19.

Destiny is also open to collaborations involving its earlier programmes and expanding its pipeline of microbiome assets.
Ticker:
DEST
Exchange:
AIM
Company Type:
Publicly Traded Company
Company Website:
Company HQ State:
Not Provided
Company HQ Country:
United Kingdom
Year Founded:
1997
Main Therapeutic Focus:
Lead Product in Development:
NTCD-M3
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
2
Speaker
photo
Chief Business Officer
Destiny Pharma plc